The cytoprotective effect of amifostine in acute radiation dermatitis: a retrospective analysis

Kouvaris, J; Kouloulias, V; Kokakis, J; Matsopoulos, G; Myrsini, B; Vlahos, L

dc.contributor.author	Kouvaris, J	en
dc.contributor.author	Kouloulias, V	en
dc.contributor.author	Kokakis, J	en
dc.contributor.author	Matsopoulos, G	en
dc.contributor.author	Myrsini, B	en
dc.contributor.author	Vlahos, L	en
dc.date.accessioned	2014-03-01T01:52:12Z
dc.date.available	2014-03-01T01:52:12Z
dc.date.issued	2002	en
dc.identifier.issn	1167-1122	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/26595
dc.subject	amifostine	en
dc.subject	cytoprotection	en
dc.subject	dermatitis	en
dc.subject	radiotherapy	en
dc.subject	retrospective study	en
dc.subject.classification	Dermatology	en
dc.subject.other	COLONY-STIMULATING FACTOR	en
dc.subject.other	TREATMENT TIME	en
dc.subject.other	NORMAL-TISSUES	en
dc.subject.other	RECTAL-CANCER	en
dc.subject.other	NECK-CANCER	en
dc.subject.other	WR-2721	en
dc.subject.other	RADIOTHERAPY	en
dc.subject.other	SKIN	en
dc.subject.other	CARCINOMA	en
dc.subject.other	TOXICITY	en
dc.title	The cytoprotective effect of amifostine in acute radiation dermatitis: a retrospective analysis	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2002	en
heal.abstract	To study the impact of amifostine as a cytoprotective agent against acute radiation dermatitis, we reviewed 220 patient records. One hundred cancer patients, with tumors localised in the pelvis (bladder, rectum, prostatic carcinomas, or gynecological cancer), who received radiotherapy and cytoprotective treatment with intravenous infusion of amifostine (group A) were included in this study. Retrospectively, we randomly selected from a database in Our hospital 120 historical controls, who received only radiotherapy without cytoprotection (group B). Mean gross dermatitis score (MGDS) was the mean value of recorded acute radiation dermatitis according to common toxicity criteria. In group A versus B patients, a significantly reduced severity of dermatitis (P < 0.001, Fisher's exact test) and significant reduction of MGDS as well as mean interruption treatment time (P < 0.001, Mann-Whitney U test) was observed. The relative risk of the outcome of the two study groups was 0.23 (95% CI: 0.15 to 0.34). The significant dermato-cytoprotective effect of amifostine noticed in our retrospective analysis warrants further investigation with randomised trials.	en
heal.publisher	JOHN LIBBEY EUROTEXT LTD	en
heal.journalName	EUROPEAN JOURNAL OF DERMATOLOGY	en
dc.identifier.isi	ISI:000178543900011	en
dc.identifier.volume	12	en
dc.identifier.issue	5	en
dc.identifier.spage	458	en
dc.identifier.epage	462	en